Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The gut fungal community, or “mycobiome,” may help predict and improve the efficacy of PD-1/PD-L1 immunotherapy in cancer. Researchers identified two overarching mycobiome profiles with distinct treatment associations (1).
The favorable profile includes higher fungal and bacterial diversity, more butyrate-producing bacteria, and metabolic pathways associated with butyrate production. Patients with this profile responded better to immunotherapy (1).